EMAIL THIS PAGE TO A FRIEND

Cell death & disease

Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease.


PMID 25210802

Abstract

Given the complex heterogeneity of pathological changes occurring in Alzheimer's disease (AD), any therapeutic effort absolutely requires a multi-targeted approach, because attempts addressing only a single event may result ineffective. Palmitoylethanolamide (PEA), a naturally occurring lipid amide between palmitic acid and ethanolamine, seems to be a compound able to fulfill the criteria of a multi-factorial therapeutic approach. Here, we describe the anti-inflammatory and neuroprotective activities of systemic administration of PEA in adult male rats given intrahippocampal injection of beta amyloid 1-42 (Aβ 1-42). Moreover, to investigate the molecular mechanisms responsible for the effects induced by PEA, we co-administered PEA with the GW6471, an antagonist of peroxisome proliferator-activated receptor-α (PPAR-α). We found that Aβ 1-42 infusion results in severe changes of biochemical markers related to reactive gliosis, amyloidogenesis, and tau protein hyperphosphorylation. Interestingly, PEA was able to restore the Aβ 1-42-induced alterations through PPAR-α involvement. In addition, results from the Morris water maze task highlighted a mild cognitive deficit during the reversal learning phase of the behavioral study. Similarly to the biochemical data, also mnestic deficits were reduced by PEA treatment. These data disclose novel findings about the therapeutic potential of PEA, and suggest novel strategies that hopefully could have the potential not just to alleviate the symptoms but also to modify disease progression.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB4300464
Anti-APP (Ab-668) antibody produced in rabbit, affinity isolated antibody
SAB2100135
Anti-APP (ab2) antibody produced in rabbit, affinity isolated antibody
SAB2100136
Anti-APP (ab3) antibody produced in rabbit, IgG fraction of antiserum
SAB2502012
Anti-APP (N-terminal) antibody produced in goat, affinity isolated antibody, buffered aqueous solution
HPA001462
Anti-APP antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4200535
Anti-APP antibody produced in rabbit, ~1.0 mg/mL, affinity isolated antibody
SAB3500274
Anti-APP antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB5200113
Anti-APP antibody produced in rabbit, 1 mg/mL, affinity isolated antibody
SAB2107345
Anti-APP antibody produced in rabbit, affinity isolated antibody
WH0000351M1
Monoclonal Anti-APP antibody produced in mouse, clone 2C12, purified immunoglobulin, buffered aqueous solution
SAB4100500
Monoclonal Anti-APP antibody produced in mouse, clone APP-B434, culture supernatant
SAB4100456
Monoclonal Anti-METAP2 antibody produced in mouse, clone METAP2-A393, culture supernatant
SAB2100134
Anti-APP (ab1) antibody produced in rabbit, affinity isolated antibody
SAB1407082
Anti-METAP2 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB2106270
Anti-APP antibody produced in rabbit, affinity isolated antibody